Edgewise Therapeutics, Inc. SEC Filings

Edgewise Therapeutics, Inc. (EWTX) reported a routine equity compensation grant to a director on a Form 4. On November 19, 2025, the reporting person received stock options to purchase 45,150 shares of common stock at an exercise price of $22.34 per share. These options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, so full vesting occurs over three years as long as the director continues as a service provider through each vesting date. The options have an expiration date of November 19, 2035, meaning they can be exercised anytime after vesting and before that date, subject to the applicable plan and agreement terms.

Edgewise Therapeutics, Inc. (EWTX) director files Form 3 reporting no holdings. The filing states that director Christopher Nathan Martin, through his attorney-in-fact, filed an initial statement of beneficial ownership and reported that he does not beneficially own any Edgewise Therapeutics securities as of the event date.

Edgewise Therapeutics, Inc. (EWTX) reported that its Board of Directors appointed Christopher Martin as a Class I director, with his term running through the company’s 2028 annual meeting of stockholders. Martin, age 49, brings extensive commercial experience from roles at Verona Pharma, SK Life Science, Cempra, and Salix Pharmaceuticals, including leading launch strategies for several first‑in‑class products.

Martin was deemed independent under SEC and Nasdaq rules and has no related‑party transactions requiring disclosure. He will receive an annual cash retainer of $40,000 for board service and a stock option grant with a grant date fair value of approximately $700,000, vesting in equal monthly installments over 36 months, with full vesting upon a Change in Control as defined in the company’s 2021 Equity Incentive Plan.

Edgewise Therapeutics (EWTX) filed a Form 4 showing insider activity. On 11/12/2025, a Director and Chief Scientific Officer exercised stock options and sold shares the same day. The insider exercised 100,000 options at an exercise price of $0.18 (code M) and sold 100,000 shares of common stock at an average price of $21.1245 (code S), with trades executed between $21.00 and $21.35.

Following these transactions, the insider directly beneficially owned 23,400 common shares. In addition, 1,147,365 derivative securities (stock options) remained beneficially owned. The exercised option referenced had become exercisable on 06/27/2021 and carries an expiration date of 06/27/2032.

Edgewise Therapeutics, Inc. director reports open-market share purchase. A reporting person who serves as a director of Edgewise Therapeutics, Inc. (EWTX) bought 10,700 shares of common stock on 11/11/2025 in an open-market transaction coded as a purchase. The shares were acquired at an average price of $18.6358 per share, with multiple trades executed in a price range from $18.55 to $18.65. Following this transaction, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held directly. The reporting person has indicated a willingness to provide detailed trade-by-trade pricing information upon request.

Edgewise Therapeutics, Inc. (EWTX) reported new equity awards to its Chief Financial Officer, Michael Nofi. On 11/10/2025, he received 43,750 restricted stock units (RSUs) that convert into the same number of common shares, vesting in four equal annual installments beginning on November 10, 2026. He was also granted stock options to purchase 262,500 shares of common stock at an exercise price of $18.28 per share. One quarter of these options vest on November 10, 2026, and the remaining options vest in equal monthly installments over the following three years, contingent on his continued service.

Edgewise Therapeutics, Inc. (EWTX) filed an initial ownership report on Form 3 for its Chief Financial Officer, who is an officer of the company but not a director or 10% owner. The event date for this ownership report is 11/10/2025. The filing states in the remarks that no securities are beneficially owned, indicating that the reporting person did not hold Edgewise Therapeutics equity at the time of this Form 3. The form is filed by one reporting person, with the signature provided by an attorney-in-fact under a power of attorney.

Edgewise Therapeutics (EWTX) appointed Michael Nofi as Chief Financial Officer, effective November 10, 2025, following the immediate retirement of CFO Michael Carruthers. The company stated Mr. Carruthers’ decision was not due to any disagreement. To support continuity, he is expected to remain an at-will employee until January 31, 2026 and then serve as a consultant until October 31, 2026.

Mr. Nofi brings 30+ years of finance leadership across life sciences, including six years as Chief Accounting Officer at SpringWorks Therapeutics. His compensation includes a $465,000 annual base salary and a target cash bonus equal to 40% of base salary. He will receive a stock option for 262,500 shares vesting 25% after one year and monthly thereafter over three years, and 43,750 restricted stock units vesting in four equal annual installments, each subject to continued service.

Edgewise Therapeutics (EWTX) filed its Q3 2025 10-Q, reporting a net loss of $40.7 million on operating expenses of $46.9 million. Research and development was $37.5 million and general and administrative was $9.4 million. Interest income contributed $6.2 million.

Liquidity remained strong with cash, cash equivalents and marketable securities of $563.3 million as of September 30, 2025, supported by an April 2025 underwritten registered direct offering of 9,935,419 shares at $20.13 per share for $200.0 million gross ($187.1 million net). For the first nine months, net cash used in operations was $105.2 million, reflecting continued investment in pipeline programs.

The company advanced multiple clinical assets: sevasemten in Phase 2 trials for Becker and Duchenne muscular dystrophy (including a pivotal cohort in Becker), EDG‑7500 in a multipart Phase 2 for hypertrophic cardiomyopathy, and EDG‑15400 in a Phase 1 study. Shares outstanding were 105,761,949 as of September 30, 2025, and 105,868,434 as of October 31, 2025. Management believes current liquidity will fund operations for at least the next 12 months.